Pharmaceutical · Fiscal year end Mar 31

Takeda Pharmaceutical Company Limited

4502

武田薬品工業株式会社

FIGI BBG000BJPPH44502.T4502 JPCorp. no. 2120001077461

Latest half-year results

First half · fiscal year to 2027-03 · filed 2026-10-29

For the first half of the fiscal year to 2027-03: Revenue ¥2.41 trillion (+8.4% YoY), Profit before tax ¥318.7 billion (+78.2% YoY), Net income ¥305.6 billion (+171.8% YoY).

	This period	Year on year
Revenue	¥2.4tn	+8.4%
Profit before tax	¥318.7bn	+78.2%
Net profit to owners	¥305.6bn	+171.8%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4502/earnings-releases.

Financials

IFRS · consolidated · fiscal year to 2026-03-31

Revenue: ¥4.5tn
Net income: −¥152.4bn
ROE: -2.1%
Equity ratio: 47.9%
Dividend / share: ¥200
Employees: 47,029

Revenue · ¥tn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥4.5tn	−¥0.2tn	¥15.5tn	¥7.4tn	-2.1%	¥-96.75	¥1.0tn
2025-03-31	¥4.6tn	¥0.1tn	¥14.2tn	¥6.9tn	1.5%	¥68.36	¥1.1tn
2024-03-31	¥4.3tn	¥0.1tn	¥15.1tn	¥7.3tn	2.1%	¥92.09	¥0.7tn
2023-03-31	¥4.0tn	¥0.3tn	¥14.0tn	¥6.4tn	5.3%	¥204.29	¥1.0tn
2022-03-31	¥3.6tn	¥0.2tn	¥13.2tn	¥5.7tn	4.2%	¥147.14	¥1.1tn

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	-2.1	5.6
Ordinary margin	-0.0316	6.6
Equity ratio, %	47.9	38.4
Revenue growth	-0.0166	19.3
Net income growth	-2.412	4
Operating cash flow / assets	0.0671	52.1

Policy-uncertainty measure0.61 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Trade & tariffs 2 Fiscal & tax 3 Regulation 4 Politics & geopolitics 2

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change +0.75pt in 90 days; 0.1% held by other listed companies.

Results wording balance: +0.23. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥4.9tn of reported debt repriced by 50 basis points, a year's interest would rise by ¥24.4bn, 2.3% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4502/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-06-17: see filing 上記評価基準に基づき評価手続きを実施した結果、当事業年度の末日である2026年3月31日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Latest voting result: 2026-06-24 · 剰余金の処分の件 · passed. /v1/companies/4502/voting

Ownership changes

All companies →

2026-10-21

Increase+0.10pt

BlackRock Japan Co., Ltd. raised holdings in Takeda Pharmaceutical Company Limited (4502) to 9.18% from 9.08%.

S100Z8ZQFiler profile Original filing (PDF, Japanese)
2026-09-17

Increase+0.65pt

BlackRock Japan Co., Ltd. raised holdings in Takeda Pharmaceutical Company Limited (4502) to 9.08% from 8.43%.

S100Z2WEFiler profile Original filing (PDF, Japanese)
2025-09-19

Decrease−0.14pt

Sumitomo Mitsui Trust Asset Management Co.,Ltd. reduced holdings in Takeda Pharmaceutical Company Limited (4502) to 5.27% from 5.41%.

S100WPC9Filer profile Original filing (PDF, Japanese)
2025-04-17

Increase+1.10pt

BlackRock Japan Co., Ltd. raised holdings in Takeda Pharmaceutical Company Limited (4502) to 8.43% from 7.33%.

S100VMSKFiler profile Original filing (PDF, Japanese)
2024-04-18

Increase+1.02pt

BlackRock Japan Co., Ltd. raised holdings in Takeda Pharmaceutical Company Limited (4502) to 7.33% from 6.31%.

S100TAGDFiler profile Original filing (PDF, Japanese)
2023-10-19

Decrease−0.50pt

Sumitomo Mitsui Trust Asset Management Co.,Ltd. reduced holdings in Takeda Pharmaceutical Company Limited (4502) to 5.41% from 5.91%.

S100S19ZFiler profile Original filing (PDF, Japanese)
2022-12-06

Increase+0.90pt

Sumitomo Mitsui Trust Asset Management Co.,Ltd. raised holdings in Takeda Pharmaceutical Company Limited (4502) to 5.91% from 5.01%.

S100PQK6Filer profile Original filing (PDF, Japanese)

5% filings

Large shareholding reports on 4502

Filed	Filer	Stake	Change	Stated purpose
2026-10-21	BlackRock Japan Co., Ltd.	9.18%	+0.10pt	pure investment
2026-09-17	BlackRock Japan Co., Ltd.	9.08%	+0.65pt	pure investment
2025-09-19	Sumitomo Mitsui Trust Asset Management Co.,Ltd.	5.27%	−0.14pt	—
2025-04-17	BlackRock Japan Co., Ltd.	8.43%	+1.10pt	pure investment
2024-04-18	BlackRock Japan Co., Ltd.	7.33%	+1.02pt	pure investment
2023-10-19	Sumitomo Mitsui Trust Asset Management Co.,Ltd.	5.41%	−0.50pt	—
2022-12-06	Sumitomo Mitsui Trust Asset Management Co.,Ltd.	5.91%	+0.90pt	—

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 4 issues
Book value: ¥8.3bn
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 1
Held by listed cos.: 12

Holds	Book value	Shares vs. prior year	Mutual
ASKA Pharmaceutical Holdings CO., Ltd. 4886	¥5,203m	0.0%	both reports
Chordia Therapeutics,Inc 190A	¥1,324m	0.0%	no
Noile-Immune Biotech Inc. 4893	¥1,169m	0.0%	no
Ovid Therapeutics, Inc.	¥631m	0.0%	no

Held by: MEDIPAL HOLDINGS CORPORATION 7459, Iyogin Holdings,Inc. 5830, Iyogin Holdings,Inc. 5830, Taikisha Ltd. 1979, Daito Pharmaceutical Co., Ltd. 4577, ASKA Pharmaceutical Holdings CO., Ltd. 4886, RAIZNEXT Corporation 6379, TOMONY Holdings,Inc. 8600, OHKI HEALTHCARE HOLDINGS CO.,LTD. 3417, TSUMUGU Holdings, Inc. 3055, Astena Holdings Co., Ltd. 8095, KOBAYASHI PHARMACEUTICAL CO.,LTD. 4967 and 1 more

Purposes, all holdings and mutual flags via /v1/companies/4502/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
日本マスタートラスト信託銀行株式会社（信託口）	266,860,000	16.84%
株式会社日本カストディ銀行（信託口）	85,053,000	5.37%
THE BANK OF NEW YORK MELLON AS DEPOSITARY BANK FOR DEPOSITARY RECEIPT HOLDERS	71,655,000	4.52%
STATE STREET BANK AND TRUST COMPANY 505001	46,685,000	2.95%
THE CHASE MANHATTAN BANK, N.A. LONDON SECS LENDING OMNIBUS ACCOUNT	38,731,000	2.44%
JP MORGAN CHASE BANK 385642	24,242,000	1.53%
JP MORGAN CHASE BANK 385781	23,394,000	1.48%
SMBC日興証券株式会社	22,142,000	1.40%
JPモルガン証券株式会社	20,021,000	1.26%
バークレイズ証券株式会社	18,406,000	1.16%

U.S. funds holding 4502

SEC Form N-PORT, reports to 2026-07-31

358 U.S. funds held 236,351,160 shares worth $7.87bn.

Fund	Shares	Value	% of fund	As of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS	23,301,746	$800.1m	0.124%	2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS	15,464,832	$492.9m	0.156%	2026-06-30
Capital World Growth & Income Fund Capital World Growth & Income Fund	13,812,291	$443.9m	0.278%	2026-05-31
iShares Core MSCI EAFE ETF iShares Trust	11,628,780	$399.3m	0.210%	2026-07-31
Capital Income Builder Capital Income Builder	10,077,550	$349.2m	0.268%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4502
GET /v1/companies/4502/financials
GET /v1/companies/4502/details
GET /v1/companies/4502/segments
GET /v1/companies/4502/voting
GET /v1/companies/4502/tender-offers
GET /v1/companies/4502/indicators
GET /v1/companies/4502/earnings-releases
GET /v1/events?ticker=4502
GET /v1/companies/4502/trades         
GET /v1/companies/4502/cross-holdings 
GET /v1/companies/4502/brief

Plans from $9 a month · Documentation